Ekso Bionics Holdings Inc. news has covered its exoskeleton technology business for medical and industrial applications, including robotic systems designed to support mobility, strength, endurance, and rehabilitation. Company updates include financial results, product and distribution activity, sales trends for Enterprise Health devices and Ekso Indego Personal devices, and rehabilitation offerings such as MediTouch’s BalanceTutor system and eksoUniversity continuing education courses.
Recurring corporate developments also include material agreements, shareholder voting matters, capital-structure disclosures, governance actions, and the completed formation of ChronoScale through a strategic combination involving EKSO Bionics.
Ekso Bionics Holdings (Nasdaq: EKSO) has completed a registered direct offering of 1,747,704 shares at $4.5145 each, raising approximately $7.89 million in gross proceeds. Additionally, the company issued warrants for up to 873,852 shares at an exercise price of $5.18, with a term of 5.5 years. Proceeds will be allocated for working capital and general corporate purposes. The offering complies with Nasdaq rules and was facilitated by H.C. Wainwright & Co.
Ekso Bionics Holdings (Nasdaq: EKSO) announced that the Committee on Foreign Investment in the U.S. (CFIUS) has raised national security concerns regarding their joint venture with Zhejiang Youchuang Venture Capital Investment Co. The CFIUS has issued a National Security Agreement, requiring the termination of Ekso's role in the venture. Established in 2019, the joint venture aimed to develop the exoskeleton market in Asia. CEO Jack Peurach expressed disappointment but affirmed the termination will not significantly impact 2020 operations.
Summary not available.